key: cord-0732880-b7aghp2s
authors: Khan, Shahzad; Rasool, Sahibzada Tasleem; Ahmed, Syed Imran
title: Role of Cardiac Biomarkers in COVID-19: What Recent Investigations Tell Us?
date: 2021-03-19
journal: Curr Probl Cardiol
DOI: 10.1016/j.cpcardiol.2021.100842
sha: f45b7a5e2bff7021c674cfdf0db153f2d1dbe447
doc_id: 732880
cord_uid: b7aghp2s

PURPOSE OF REVIEW: Although the respiratory system is the main target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is evident from recent data that other systems, especially cardiovascular and haematological, are also significantly affected. In fact, in severe form, COVID-19 causes a systemic illness with widespread inflammation and cytokine flood, resulting in severe cardiovascular injury. Therefore, we reviewed cardiac injury biomarkers' role in various cardiovascular complications of COVID 19 in recent studies. RECENT FINDINGS: Cardiac injury biomarkers were elevated in most of the complicated cases of COVID-19, and their elevation is directly proportional to the worst outcome. Evaluation of cardiac biomarkers with markers of other organ damage gives a more reliable tool for case fatalities and future outcome. SUMMARY: Significant association of cardiac biomarkers in COVID-19 cases helps disease management and prognosis, especially in severely ill patients.

Cardiac biomarkers are mainly a measurable protein produced as a result of some pathological processes in the cardiovascular system. To be clinically useful, they ought to be of high sensitivity, specificity, and cost-effectiveness. In clinical practice, cardiac biomarkers are now a frequently used technique to identify the presence and progression of cardiovascular diseases [1••-3] . In current clinical practice, cardiac biomarkers are routinely used in combination with other diagnostic tools such as electrocardiography, echocardiography, and radiodiagnostics. The prime objective of cardiac biomarkers in cardiology is mainly an adjuvant diagnostic technique which in many circumstances could be of extremely useful in the care of the patient [2] .

Cardiac biomarkers are important in various cardiovascular conditions such as Congestive heart failure (CHF), ischemic heart diseases (IHD), diabetic cardiomyopathy (DCM), acute coronary syndromes (ACS), and acute myocardial infarction (AMI). Various notable cardiac biomarkers include natriuretic peptides, like b-type natriuretic peptide (BNP), N-terminal pro-b-type natriuretic peptide (Nt-proBNP) and mid regional pro-atrial natriuretic peptide (MR-pro ANP), cardiac troponin T (CTnT), cardiac troponin I (CTnI), soluble source of tumorigenicity 2 (sST2), galectin-3 (Gal-3), and growth differentiation factor-15 (GDF-15).

Recently various micro ribonucleic acids (miRNAs) are also successfully used as cardiac biomarkers. Table 1 .

Although the SARS novel coronavirus (SARS-CoV-2) or COVID-19 is a viral illness in which lungs are the primary and severely affected target as the name suggests but in fact, it is a system illness in which most of the organ systems are affected with varying degree. The severity of the disease depends on factors such as the age of the patient, immune status, and preexisting comorbidities. The disease gradually progresses and evolves, and the signs and symptoms depend on the viral infiltration and replication and host immune response. The disease progression over time can be divided into three stages, early infection stage, a pulmonary stage, and a severe hyper inflammation stage in which systemic complications are likely to result ( Table 2 ). In the first stage, viral infiltrate and replicate, and lymphopenia is observed. Later as the disease progresses, lung involvement increases, resulting in various respiratory signs and symptoms. In this stage, radiographic imaging can also detect lung involvement. As the disease progresses, the body's immune system tries to control and limit the viral damage, but unfortunately, this results in an exaggerated hyperinflammatory response, causing extensive collateral tissue damage and severely affecting many organs. In this stage, cardiac and vascular systems are no exception, and cardiovascular injury can be severe and fatal [4••-6•] .

There are various patterns of cardiovascular involvement in COVID 19. First of all, cardiovascular disease present as pre-existing comorbidity which becomes apparent or becomes more complicated and decompensated during COVID 19. Second cardiovascular system involvement results due to systemic inflammatory response during the course COVID 19. The third cardiovascular system can be affected during treatment due to the side effects of some medication or secondary hospital-acquired infections and complications. Table 3 shows significant cardiovascular comorbidities and mortalities found in COVID 19.

Severe acute respiratory syndrome coronavirus 2 or (SARS-CoV-2) is responsible for the coronavirus disease of 2019 or . COVID 19 can affect the cardiovascular system (CVS) in a variety of ways. COVID 19 associated cardiovascular diseases (CVD) can be classified as primary CVD (resulting from direct viral injury) such as arrhythmias, acute coronary syndrome (ACS), and myocarditis and secondary CVD (resulting from an exaggerated systemic inflammatory response) such as a cardiac injury during multiple organ failure (MOF) in septic shock of SARS-CoV-2. There is considerable overlap between primary CVD and secondary CVD, which makes the distinction very difficult, especially when the disease is severe or the disease course is rapid, or the patient is older or the presence of other comorbidities [7] . We will briefly discuss these CVD and then present the importance of cardiac biomarkers in the diagnostics and therapeutics of COVID 19.

Investigations have shown that viral infections are associated with coronary plaque inflammation, may promote plaque rupture, and can initiate thrombosis. It is believed that COVID19 is likely to behave likewise and patients with COVID19 can present with the acute coronary syndrome (ACS) [8] [9] [10] . The COVID 19 patients can present with non-ST segment elevation (NSTEMI) as well as with ST-segment elevation (STEMI). However, COVID-19 patients may present without classic symptoms of angina. Alternatively, other conditions may mimic ACS, such as myocarditis and pericarditis. Therefore, a complete investigation with electrocardiography (ECG), echocardiogram, and cardiac biomarkers is mandatory [11••, 12••] . In a small-scale study, COVID 19 33% of patients presented with chest pain and 78% with ST-segment elevation. On echocardiography, 35% of them had regional wall motion abnormality, and half of them had to go through coronary angiography in which 67% confirmed with coronary occlusion [13] .

The possible mechanism of cardiac injury is believed to be through multiple overlapping factors such as In contrast, a recent autopsy study of cardiac tissue of 39 cases from Germany found SARS-CoV-2 in 24 of 39 patients (61.5%) with a viral load above 1000 copies per μg RNA in 16 of 39 patients (41.0%). The study also reported a higher cytokine response and expression of many proinflammatory genes in these 16 patients compared with 15 patients without any SARS-CoV-2 in the heart. This result indicates that severe cardiac injury is more likely in cases with higher virus load. The same study revealed that the localization of SARS-CoV-2 was most likely in interstitial cells or macrophages of myocardial tissue rather than the cardiomyocytes [21••] . Alternatively, other EMB studies also found SARS-CoV-2 in cardiac macrophages but did not find cardiomyocytes [22••] . According to reports, 25% of COVID 19 patients have a myocardial injury and show elevated cardiac troponin (CTn) [23••-26••] . According to studies, the rapid increase of cardiac biomarkers, including CTn, CRP (C-reactive protein), D-dimer, NT-pro-brain natriuretic peptide (NTpro BNP) especially during the late course of disease indicate poor prognosis with case fatality [25] .

Congestive heart failure (CHF) patients are at higher risk of getting SARS-CoV-2 infection, an ominous sign because the severe respiratory disease itself can result in CHF decompensation [27] . Increased levels of serum brain natriuretic peptide (BNP) may indicate the contribution of cardiac failure in pulmonary oedema frequently seen in COVID 19 patients, which is mainly because of acute respiratory distress syndrome (ARDS) [29] . In contrast, some cases of COVID-19 have shown raised BNP levels 

Shock with or without multi-system organ failure (MOF) is a hallmark of severe COVID-19. The shock can be multifactorial, usually septic shock, though the cardiogenic shock is also commonly seen if CHF or myocarditis is also present [31••] . Septic shock frequently results in disseminated intravascular coagulation (DIC), which is an important reason for the high incidents of thromboembolism seen in COVID 19 [35••] .

Patients with COVID-19 infection are at high risk for venous and arterial thromboembolism in COVID 19. In 

There are reports available that show COVID 19 can result in arrhythmias, especially where the coexisting myocardial injury is also present. This verdict is proved by a study that showed the incidence of malignant arrhythmias were higher in subjects with proven myocardial injury (17.3% versus 1.5%) [24••] . Various forms of arrhythmias have been reported in COVID 19 which include non-shockable such as asystole (89.7%), pulseless electrical activity (4.4%), as well as shockable (5.9%) such as ventricular fibrillation and pulseless ventricular tachycardia [45••] .

Arrhythmias in COVID 19 may be due to side effects of drug treatment such as hydroxychloroquine, which is known to prolong corrected QT Interval (QTc). Prolonged QTc is associated with ECG findings called 

Cardiac biomarkers can play an essential role in the diagnosis, management, and prognosis of COVID 19.

However, usually, cardiac biomarkers are increased in various cardiac pathologies, but they can be increased in some pulmonary diseases as well. If there are preexisting lung comorbidity, which is frequently present in COVID 19 patients, cardiac biomarkers may indicate a mixed pathology. Previous studies have shown increased cardiac biomarkers in various lung pathologies. For example, a study showed, elevated Nt-proBNP at the time of discharge in chronic obstructive pulmonary disease (COPD) patients, was associated with increased risk of re-hospitalization and mortality. Additionally, CTnT is also linked with poor prognosis in pulmonary embolism [53] and with stable ischemic heart disease of type2-diabetes mellitus(T2DM) patients [54] .

A study of 730 community-acquired pneumonia (CAP) patients showed that biomarkers pro adrenomedullin (pro-ADM), pro-endothelin-1, troponin, proBNP, and IL-6 levels were significantly increased in patients who also suffered cardiovascular events during the early (one month) and late (up to one year) follow up period.

These cardiac events included acute coronary syndrome, acute myocardial infarction, unstable angina, new or worsening arrhythmia, atrial fibrillation, atrial flutter, acute heart failure, cerebrovascular accident, stroke, and transient ischemic attack. This study showed the importance of cardiac biomarkers in managing longterm cardiovascular complications in CAP patients [55••] .

As discussed earlier, multiple preexisting or new-onset cardiac pathologies in COVID-19 can lead to Proofs of the strong association of troponins (CTnI and CTnT) with COVID19 have not been found. A study from the Netherlands [65] between April 1 to May 12, 2020, totalling 51 patients found no relation between elevated CTnT, NT-proBNP, and ventricular dysfunction. This finding supports the results of another investigation [26••] , which found that the cTnI level was only slightly increased in all COVID 19 patients [66••] . However, the study found that cTnI levels were significantly increased in severe COVID 19 cases compared to milder COVID 19 cases. Hence the study strongly suggested serial measurement of CTnI and CTnT to identify patients with a possible cardiac injury during COVID-19 [26••] .

A unique cardiac mortality prediction model in COVID 19 has been proposed in a recent meta-analysis of 17 794 patients [67••] . This model recommends combined evaluation of aspartate aminotransferase (AST) with CTnI and advanced age and suggests that high CTnI (more than 13.75 ng/L) combined with either advanced age (more than 60 years) or elevated AST level (more than 27.72 U/L) is the best model for prediction of poor outcomes. Since cardiac injury is frequently a part of multi-organ damage of septic shock of SARS-CoV-2, this combined assessment of cardiac injury biomarkers with liver injury biomarker and advanced age seems plausible. The role of cardiac biomarkers in the better prediction of future mortality has been investigated in a recent study. The study was conducted on 3,219 SARS-CoV-2 positive patients and observed the role of cardiac biomarkers in an effective prognosis of 28-day mortality. This study found cardiac biomarkers very useful and suggested much lower cutoff levels of hs-cTnI, NT-proBNP, CK-MB, and myoglobin than the current reference standards for the prognosis of mortality in COVID-19 patients

After reviewing results from most recent studies on COVID19 patients, it is evident that direct or indirect cardiac involvement is not uncommon in COVID19. The degree of cardiac injury is variable, and severity depends on the age of the patient, preexisting cardiac disease, and the pathophysiology involved in cardiac injury. Cardiac biomarkers increase in most of the COVID19 patients, though their prognostic power for worst outcome increases with the severity of the disease, and lower threshold of cardiac biomarkers would be applicable for diagnosis and prognosis. A combined evaluation of cardiac biomarkers with markers of other organ damage is likely to give a better picture of the future outcome because the septic shock of SARS-CoV-2 is frequently associated with multi-organ damage. A better description of the role and use of cardiac biomarkers in COVID 19 is quite likely in the future.

All authors contributed to the concept and manuscript and final approval for manuscript submission.

There is no funding involved in the writing of this article.

The authors declare no conflict of interest.

This article does not contain any studies with human or animal subjects performed by any of the authors. 

Coronary artery disease 10% to 17% Hypertension from 35% to 57%, Congestive heart failure (CHF) 6% to 7% (Non -ICU patients)

Congestive heart failure (CHF) 42.9% (ICU patients) COVID-related deaths having underlying CVD 30% to 35%

A fresh article which discusses the recent findings about Cardiac Biomarkers

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Trends in prevalence and outcome of heart failure with preserved ejection fraction

Transplantation L. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Natural regulatory T cells in infectious disease

A very important article about the immunopathology of Human coronaviruses (hCoVs) and severe acute respiratory syndrome CoV

Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age

Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein Edeficient mice

Association of coronary plaque rupture and atherosclerotic inflammation

Clinical pathway for management of suspected or positive novel coronavirus-19 patients with ST-segment elevation myocardial infarction

The variety of cardiovascular presentations of COVID-19. 2020. Very important article about cardiovascular complications in COVID 19 patients

ST-segment elevation in patients with Covid-19-a case series

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

COVID-19 and cardiovascular disease

A review of various most recent articles about cardiovascular outcomes in COVID-19 patients emphasizes health care workers

Endothelial dysfunction: a marker of atherosclerotic risk

Since SARS-CoV-2 infects through the angiotensin-converting enzyme 2 (ACE2) receptor, which is also expressed by endothelial cells, the article investigates the possibility of SARS-CoV-2 direct infection to the endothelial cell of vascular beds of different organs

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts

Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. 2020. This is a recent analysis of various autopsy cases investigating the SARS-COV 2 presence within COVID 19 patients' myocardium

Myocardial localization of coronavirus in COVID-19 cardiogenic shock. 2020. Article describe the first case of acute cardiac injury

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. 2020. This recent case series report discusses the characteristics and outcomes in a large group of hospitalized patients with confirmed COVID-19 in the

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). 2020. A recent investigation about the cardiovascular involvements and fatal outcomes in COVID-19 patients

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. 2020. A recent investigation from China about the cardiovascular implications and risk factors with fatal outcomes in COVID-19 patients

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. 2020. This article emphasizes on the importance of measurement of cardiac damage biomarkers in SARS-CoV-2 infection

Predictors and outcomes of infection-related hospital admissions of heart failure patients

A recently conducted small but important study of critically ill patients from Washington State which investigated the characteristics

Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema

Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. 2020. A unique case report in which a patient with COVID 19 presented with heart damage and not lung complaints

Approach to Acute Cardiovascular Complications in COVID-19 Infection. 2020. A comprehensive article that focuses on the management of cardiovascular complication of COVID 19

Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?

Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). 2020. This article discusses the COVID 19 and ACE2 receptor relationship. However, the study found no association between ACEI or ARB use and COVID-19 test positivity

Renin-angiotensinaldosterone system inhibitors and risk of Covid-19. 2020. A fresh study which investigates the relationship of Renin-angiotensin-aldosterone system and Covid-19

Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 Patients. 2020:100648. A recent study investigating coagulability disorder in and Covid-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Hematologic parameters in patients with COVID-19 infection

2020:1. The largest study of autopsies of SARS-CoV-2-infected persons to date

Incidence of thrombotic complications in critically ill ICU patients with COVID-19. 2020. An important recent study investigating coagulability disorder in and Covid-19

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. 2020. An important recent study from Italy

Large-vessel stroke as a presenting feature of Covid-19 in the young

Diagnostic workup, etiologies and management of acute right ventricle failure

Pulmonary hypertension in severe acute respiratory failure

The right ventricle in ARDS

In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan

Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

The article discusses the possibility of prolonged QT interval and torsade de pointes risk during the treatment of COVID 19 with hydroxychloroquine

QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications

Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology

The article discusses the management of long QT syndrome arrhythmia

Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19). 2020. . The article discusses the risk and management of electrolyte imbalance during the treatment of COVID 19

Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease

Troponin and cardiac events in stable ischemic heart disease and diabetes

Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers

A novel coronavirus from patients with pneumonia in China

Prognostic value of Cardiac Biomarkers

Infection: A Meta-analysis. 2020. A very comprehensive study about the importance of cardiac biomarkers in COVID 19

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Elevated cardiac biomarkers are associated with increased mortality for inpatients with COVID-19: A retrospective case-control study. 2020;65:109894. A very comprehensive study about the role of cardiac biomarkers in COVID 19

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. 2020. One of the intitially conducted COVID 19 study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Impact of Congestive Heart Failure and Role of Cardiac Biomarkers in COVID-19 patients: A Systematic Review and Meta-Analysis

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19. 2020:1-8. A recent investigation about the cardiovascular involvements and outcomes in COVID-19 patients

A recent study about the role of various laboratory abnormalities in COVID 19

Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and Decision tree analysis. 2020. A very detailed study about the role of cardiac biomarkers in COVID 19 patients

Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19. 2020. Another detailed study about the role of cardiac biomarkers in COVID 19 patients

Reply to:'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19

Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy